Skip to main content

Table 1 Clinical characteristics of patients in the treatment and control groups

From: Cellular immunotherapy as maintenance therapy prolongs the survival of the patients with small cell lung cancer

Clinical features LS-SCLC P value ES-SCLC P value All patients P value
Control Study Control Study Control Study
Sex
Male 14 11 0.438 7 11 0.155 21 22 1.000
Female 3 6 5 1 8 7
Age, years
Median 61 61 0.898 58.5 62.5 0.045 60 62 0.215
Range 43–80 41–77 46–67 54–79 43–80 41–79
Smoking index
Median 400 300 0.572 600 600 0.861 500 400 0.716
Range 0–1350 0–2000 0–1200 0–1200 0–1350 0–2000
ECOG
≤1 14 15 1.000 12 10 0.478 26 25 1.000
2 3 2 0 2 3 4
Chemotherapy courses
Median 6 5 0.141 6 6 1.000 6 6 0.187
Range 4–6 4–6 4–6 4–6   4–6 4–6
Radiotherapy
Yes 17 17 1.000 6 8 0.680 23 25 0.730
No 0 0 6 4   6 4
Surgery
Yes 2 2 1.000 0 2 0.478 2 4 0.666
No 15 15 12 10 27 25
Chemotherapy responses *
CR 7 5 0.822 1 2 1.000 8 7 1.000
PR 7 8 7 6 14 14
SD 3 4 4 4 7 8
  1. Abbreviations: ECOG, Eastern Cooperative Oncology Group; CR, complete remission; PR, partial remission; SD, stable disease; LS-SCLC, limited stage small cell lung cancer; ES-SCLC, extensive stage small cell lung cancer
  2. Note: *The responses for the first-line therapy